Skip to main content

Can you take Glycerin with Revuforj?

1 drug interaction and 10 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

glycerin revumenib

Applies to: glycerin and Revuforj (revumenib)

Revumenib can cause an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.

The risk is increased if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances, such as low blood levels of magnesium or potassium

These electrolyte disturbances can occur with bowel cleansing preparations or excessive use of medications that have a laxative effect, such as glycerin.

Do not exceed the dose and duration recommended on the product label or prescribed by your doctor.

You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether taken together or separately.

In addition, you should let your doctor know if you experience signs and symptoms of low magnesium or potassium blood level such as:

  • weakness
  • tiredness
  • drowsiness
  • dizziness
  • confusion
  • tingling
  • numbness
  • muscle pain
  • cramps
  • nausea
  • vomiting

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

revumenib Food/Lifestyle

Applies to: Revuforj (revumenib)

High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).

Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.

You may be more susceptible if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)

Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.

Symptoms of differentiation syndrome include:

  • fever
  • cough
  • shortness of breath
  • severe headache
  • confusion
  • dizziness
  • rapid weight gain
  • swelling
  • decreased urination

You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.

The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.

Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

9 potential interactions Applies to: 9 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Inflammatory Bowel Disease, and Liver Disease.

Arrhythmia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Gastrointestinal Obstruction

Major:

glycerin

Glycerin has a major potential interaction with Gastrointestinal Obstruction.

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

Heart Failure

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Heart Failure.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Hypokalemia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Inflammatory Bowel Disease

Major:

glycerin

Glycerin has a major potential interaction with Inflammatory Bowel Disease.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

Liver Disease

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Liver Disease.

Revumenib has not been studied in patients with severe liver or renal impairment.

Long QT Syndrome

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Magnesium Imbalance

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Renal Dysfunction

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.

Revumenib has not been studied in patients with severe liver or renal impairment.

Report options

Loading...
QR code containing a link to this page

More resources

glycerin

A total of 267 drugs are known to interact with glycerin.

Revuforj

A total of 583 drugs are known to interact with Revuforj.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer